Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):110-8. doi: 10.1016/j.ijrobp.2014.05.023. Epub 2014 Jul 8.

Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost.

Author information

1
Department of Oncology, Vejle Hospital, Vejle, Denmark; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. Electronic address: ane.lindegaard.appelt@rsyd.dk.
2
Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
3
Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark.
4
Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center, and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.
5
Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark.

Abstract

PURPOSE/OBJECTIVE(S):

Mature data on tumor control and survival are presented from a randomized trial of the addition of a brachytherapy boost to long-course neoadjuvant chemoradiation therapy (CRT) for locally advanced rectal cancer.

METHODS AND MATERIALS:

Between March 2005 and November 2008, 248 patients with T3-4N0-2M0 rectal cancer were prospectively randomized to either long-course preoperative CRT (50.4 Gy in 28 fractions, per oral tegafur-uracil and L-leucovorin) alone or the same CRT schedule plus a brachytherapy boost (10 Gy in 2 fractions). The primary trial endpoint was pathologic complete response (pCR) at the time of surgery; secondary endpoints included overall survival (OS), progression-free survival (PFS), and freedom from locoregional failure.

RESULTS:

Results for the primary endpoint have previously been reported. This analysis presents survival data for the 224 patients in the Danish part of the trial. In all, 221 patients (111 control arm, 110 brachytherapy boost arm) had data available for analysis, with a median follow-up time of 5.4 years. Despite a significant increase in tumor response at the time of surgery, no differences in 5-year OS (70.6% vs 63.6%, hazard ratio [HR] = 1.24, P=.34) and PFS (63.9% vs 52.0%, HR=1.22, P=.32) were observed. Freedom from locoregional failure at 5 years were 93.9% and 85.7% (HR=2.60, P=.06) in the standard and in the brachytherapy arms, respectively. There was no difference in the prevalence of stoma. Explorative analysis based on stratification for tumor regression grade and resection margin status indicated the presence of response migration.

CONCLUSIONS:

Despite increased pathologic tumor regression at the time of surgery, we observed no benefit on late outcome. Improved tumor regression does not necessarily lead to a relevant clinical benefit when the neoadjuvant treatment is followed by high-quality surgery.

PMID:
25015203
PMCID:
PMC4159435
DOI:
10.1016/j.ijrobp.2014.05.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center